Results 31 to 40 of about 33,952 (165)

Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia

Cells
The landscape of adult acute lymphoblastic leukemia (ALL) is dramatically changing. With very promising results seen with novel immunotherapeutics in the setting of relapsed and refractory disease, the prospect of using these agents in first-line therapy
Oscar Sucre, Saagar Pamulapati, Zeeshan Muzammil, Jacob Bitran   +3 more
doaj   +1 more source

Multivalent Anchoring and Oriented Display of Single-Domain Antibodies on Cellulose

Sensors, 2009
Antibody engineering has allowed for the rapid generation of binding agents against virtually any antigen of interest, predominantly for therapeutic applications.
Roger MacKenzie, Jamshid Tanha, Yan Luo, Linda Veldhuis, J. Christopher Hall, Greg Hussack   +5 more
doaj   +1 more source

Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer

Cells, 2021
Antibodies against inhibitory immune checkpoint molecules (ICPMs), referred to as immune checkpoint inhibitors (ICIs), have gained a prominent place in cancer therapy.
Fabrizio Marcucci, Cristiano Rumio
doaj   +1 more source

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer

Antibodies, 2016
Bispecific antibodies offer a promising approach for the treatment of cancer but can be challenging to engineer and manufacture. Here we report the development of PF-06671008, an extended-half-life dual-affinity re-targeting (DART®) bispecific molecule ...
Adam R. Root, Wei Cao, Bilian Li, Peter LaPan, Caryl Meade, Jocelyn Sanford, Macy Jin, Cliona O’Sullivan, Emma Cummins, Matthew Lambert, Alfredo D. Sheehan, Weijun Ma, Scott Gatto, Kelvin Kerns, Khetemenee Lam, Aaron M. D’Antona, Lily Zhu, William A. Brady, Susan Benard, Amy King, Tao He, Lisa Racie, Maya Arai, Dianah Barrett, Wayne Stochaj, Edward R. LaVallie, James R. Apgar, Kristine Svenson, Lidia Mosyak, Yinhua Yang, Gurunadh R. Chichili, Liqin Liu, Hua Li, Steve Burke, Syd Johnson, Ralph Alderson, William J. J. Finlay, Laura Lin, Stéphane Olland, William Somers, Ezio Bonvini, Hans-Peter Gerber, Chad May, Paul A. Moore, Lioudmila Tchistiakova, Laird Bloom   +45 more
doaj   +1 more source

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade

Frontiers in Immunology
BackgroundThe introduction of checkpoint immunotherapeutic agents in the last decade has revolutionized cancer treatment. Although anti-PD-1, anti-PD-L1 and anti-CTLA4 are promising therapies, many patients fail to respond or relapse due to drug ...
Przemysław Bielski, Przemysław Bielski, Przemysław Bielski, Jan Barczyński, Jan Barczyński, Michał Mikitiuk, Michał Mikitiuk, Maja Myrcha, Kamil Rykała, Louis Boon, Wiktoria Gąsior, Aleksandra Hec-Gałązka, Tad A. Holak, Tomasz Sitar, Tomasz Sitar   +14 more
doaj   +1 more source

COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors

mAbs, 2020
Conditionally active COBRA™ (COnditional Bispecific Redirected Activation) T cell engagers are engineered to overcome the limitations of inherently active first-generation T cell engagers, which are unable to discern between tumor and healthy tissues ...
Anand Panchal, Pui Seto, Russell Wall, Brian J. Hillier, Ying Zhu, Jessica Krakow, Aakash Datt, Elizabeth Pongo, Andisheh Bagheri, Tseng-Hui T. Chen, Jeremiah D. Degenhardt, Patricia A. Culp, Danielle E. Dettling, Maia V. Vinogradova, Chad May, Robert B. DuBridge   +15 more
doaj   +1 more source

A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs

Pharmaceutics
Background/Objectives: All current FDA-approved antibody–drug conjugates (ADCs) are single-target and single-payload molecules that have limited efficacy in patients due to drug resistance.
Nicole A. Wilski, Peter Haytko, Zhengxia Zha, Simin Wu, Ying Jin, Peng Chen, Chao Han, Mark L. Chiu   +7 more
doaj   +1 more source

Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats

mAbs, 2020
The success of therapeutic antibodies is largely attributed for their exquisite specificity, homogeneity, and functionality. There is, however, a need to engineer antibodies to extend and enhance their potency.
Ami Miller, Stephen Carr, Terry Rabbitts, Hanif Ali   +3 more
doaj   +1 more source

Antibodies to watch in 2026

mAbs
The Antibodies to Watch article series provides annual updates on commercial late-stage clinical development, regulatory review, and marketing approvals of antibody therapeutics.
Silvia Crescioli, Hélène Kaplon, Alicia Chenoweth, Yu-Shin Hsu, Kieran Pinto, Vaishali Kapoor, Janice M. Reichert   +6 more
doaj   +1 more source

Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma: a retrospective real-world study

Frontiers in Immunology
BackgroundAt the time of diagnosis, 80% of patients with pancreatic ductal adenocarcinoma (PDAC) are already at an unresectable advanced stage. The median overall survival (mOS) with traditional AG chemotherapy is only 8.5 months. The bispecific antibody
Wenke Qin, Yan Du, Xuean Zhao, Yongqing Zhao, Yan Zhang, Shuze Zhang, Zengxi Yang, Xin Li, Jubao Niu, Dewen Zhao, Kongyuan Wei, Hui Zhang, Hui Zhang   +12 more
doaj   +1 more source